Get the Daily Brief
Latest Biotech News
Krystal reports early proof-of-concept for CF gene therapy
Krystal Biotech disclosed an early proof-of-concept clinical report for its cystic fibrosis gene therapy program, according to BioCentury’s clinical updates. Early clinical observations suggested...
Phanes posts positive Phase 2 PDAC data at ASCO GI
Phanes Therapeutics announced positive Phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, presented at ASCO GI 2026. Data showed activity in combination with...
Biotech cash flood: $4.9B pours into private and public companies ahead of JPM
Biotech companies drew an estimated $4.9 billion in fresh capital during the first full week of January, according to Endpoints News and other market tallies. The inflows included multiple...
Aktis pop: Radiopharma IPO raises $318M and fuels hopes for biotech listings
Radiopharmaceutical developer Aktis Oncology priced its IPO at $18 per share, raising roughly $318 million and sending shares sharply higher at debut. The upsized offering and positive market...
Big rounds fuel therapy launches: Mirador and Orca secure $250M each
Two private biotechs announced large financing rounds: Mirador Therapeutics raised $250 million in a Series B to expand its precision immunology pipeline and signaled IPO plans, while Orca Bio...
Krystal pushes mutation‑agnostic CF gene therapy: early PoC claims and fast path plan
Krystal Biotech disclosed early clinical data suggesting its mutation-agnostic approach can deliver native protein to cystic fibrosis patients and signaled plans to move directly into a pivotal...
Illumina taps former NHGRI chief: Eric Green named chief medical officer
Illumina appointed former NHGRI director Eric Green as chief medical officer, a hire the company said will accelerate its push into clinical genomics and precision medicine. Interviews and...
Open tools and AI platforms: Boltz launches with $28M; FRAIL advances molecular design
MIT spinout Boltz launched as a public-benefit company with a $28 million seed round to deliver open AI platforms for drug discovery, claiming AlphaFold‑level complex prediction and agents for...
Plasmids to CHO: CDMO alliances and cell‑line platforms expand biologics supply
Bionova Scientific struck a manufacturing alliance with genetic delivery company Syenex to expand global access to plasmid DNA for viral and mRNA production; the partnership will make Bionova a...
Spevatamig shows activity in 1L PDAC: Phanes posts positive phase 2 data
Phanes Therapeutics reported positive Phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, in combination with chemotherapy as first‑line treatment for...
Enzymatic oligo synthesis gains ground: ATP‑free NTP production could cut costs
Researchers at the University of Manchester reported an ATP‑free enzyme‑driven method for nucleotide triphosphate synthesis—an advance the authors argue could lower costs and environmental...
Drug pricing moves: J&J signs MFN terms; Genentech cuts PBM exposure to save millions
Johnson & Johnson announced a voluntary most‑favored‑nation (MFN) pricing agreement with the White House aimed at improving U.S. drug access, leaving AbbVie and Regeneron as the only major firms...
Biotech IPOs Return: Aktis Raises $318M; Eikon Files to Test Market
Aktis Oncology priced an upsized IPO that raised $318 million, selling shares at $18 apiece and opening trading with a sharp pop. The radiopharmaceutical developer’s debut signals renewed investor...
Merck Eyes Revolution: Talks Surface on $28–32B Takeover
Multiple outlets reported that Merck is in discussions to acquire Revolution Medicines, with deal values reported in the $28–32 billion range. The talks, if they proceed, would provide Merck with...
Krystal Posts Early CF Gene Therapy Proof: Pivotal Push Underway
Krystal Biotech disclosed early clinical data suggesting its mutation‑agnostic approach can deliver native CFTR protein to cystic fibrosis patients, and the company signaled plans to advance...
AI Drug Discovery Draws Capital: Boltz Launches; a16z Expands Bio Fund
MIT spinout Boltz launched as a public benefit corporation with a $28 million seed round to commercialize high‑accuracy AI models for biomolecular structure prediction and therapeutic design....
Plasmid Supply and CHO Capacity: Bionova-Syenex Alliance; Aragen’s CHOMax
Bionova Scientific and Syenex forged a plasmid DNA manufacturing alliance intended to expand global access to plasmids for lentiviral and mRNA production, combining Bionova’s IS‑free host platform...
New Glioblastoma Strategies: Imidazotetrazines and HDAC1 Mechanisms
Researchers reported novel imidazotetrazine derivatives that overcome temozolomide resistance in glioblastoma models, presenting a potential route to address a longstanding therapeutic gap in GBM....
Scaling Cell Therapy: Orca Raises $250M; Cellares Partners with City of Hope
Orca Bio secured $250 million to support the commercial launch of its allogeneic T‑cell therapy, a financing aimed at building manufacturing, commercialization and market access capabilities for...
Illumina Hires Eric Green: Company Pushes Into Clinical Genomics
Illumina named former NHGRI director Eric Green as chief medical officer, filling a long‑vacant role as the sequencing leader aims to accelerate clinical genomics adoption. In interviews, Green...